French National Observatory of Patients With Thymic Epithelial Tumor
NCT02724696 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3262
Last updated 2023-05-24
Summary
RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the objective of territorial coverage by regional expert centers and systematic discussion of patients management at national tumor board.
Conditions
- Thymic Epithelial Tumor
Sponsors & Collaborators
-
Intergroupe Francophone de Cancerologie Thoracique
lead OTHER
Principal Investigators
-
Benjamin BESSE, Dr · Villejuif - Gustave Roussy
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-01-31
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- France
Study Locations
More Related Trials
-
Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
NCT01809600 ·Status: COMPLETED
-
Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST)
NCT05934864 ·Status: RECRUITING
-
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT05422521 ·Status: RECRUITING ·Phase: NA
-
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
NCT05237245 ·Status: ACTIVE_NOT_RECRUITING
-
Institut Paoli Calmettes Lymphoma Database
NCT02869542 ·Status: RECRUITING
-
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
NCT01110733 ·Status: COMPLETED
-
Immunotherapy in Lymphoma
NCT06796517 ·Status: RECRUITING
-
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
NCT01461928 ·Status: COMPLETED ·Phase: PHASE3
-
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125 ·Status: UNKNOWN
-
Application of Telemedicine to the Management of Aggressive Lymphomas
NCT03336138 ·Status: COMPLETED ·Phase: NA
-
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT03493451 ·Status: COMPLETED ·Phase: PHASE2
-
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
NCT02520895 ·Status: COMPLETED
-
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
NCT04947618 ·Status: RECRUITING
-
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
NCT00169169 ·Status: TERMINATED ·Phase: PHASE3
-
TREatment of degeNerative and Neoplastic Diseases With Rituximab
NCT01277172 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941 ·Status: ACTIVE_NOT_RECRUITING
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
NCT01142674 ·Status: COMPLETED
-
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156 ·Status: RECRUITING ·Phase: PHASE2
-
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
NCT05298293 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
NCT01287923 ·Status: COMPLETED
-
Treatment of Localized Low Grade Lymphomas
NCT00536458 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma
NCT01392716 ·Status: COMPLETED ·Phase: PHASE2
-
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
NCT06788964 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
NCT02902874 ·Status: COMPLETED ·Phase: NA
-
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
NCT03985696 ·Status: UNKNOWN ·Phase: NA